Recombinant Human Thrombopoietin in Combination With Rituximab Versus Low-dose Rituximab for the Treatment of Refractory ITP
Phase of Trial: Phase III
Latest Information Update: 22 Apr 2016
Price : $35 *
At a glance
- Drugs Thrombopoietin (Primary) ; Rituximab
- Indications Thrombocytopenia
- Focus Therapeutic Use
- 19 Apr 2016 Study design changed from double blind study to open label study.
- 16 Dec 2013 New trial record
- 10 Dec 2013 Results presented at the 55th Annual Meeting and Exposition of the American Society of Hematology.